Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and raises the price target from $6 to $7.5.
Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and raises the price target from $6 to $7.5.